Antiandrogens fail to block androstenedione-mediated mutated androgen receptor transactivation in human prostate cancer cells

International Journal of Urology

Volumn 7, Issue 1, 2000, Pages 32-34

  Miyamoto, Hiroshi ^a   Chang, Chawnshang ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTENEDIONE; ANTIANDROGEN; BICALUTAMIDE; CHLORAMPHENICOL ACETYLTRANSFERASE; HYDROXYFLUTAMIDE; METRIBOLONE; TESTOSTERONE;

CANCER CELL; CASTRATION; CONTROLLED STUDY; HORMONAL THERAPY; HUMAN; HUMAN CELL; LETTER; MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE ACTIVATION; TRANSACTIVATION; TRANSCRIPTION REGULATION; TUMOR REGRESSION;

ANDROGEN ANTAGONISTS; ANDROSTENEDIONE; HUMANS; MALE; MUTATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED;

EID: 0034117346     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2000.00129.x     Document Type: Letter

References (12)

1. Garnick MB. Hormonal therapy in the management of prostate cancer: From Huggins to the present. Urology 1997; 49 (Suppl.): 5-15A.
2. Gaddipati JP, McLeod DG, Heidenberg HD et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 1994; 54: 2861-4.
3. Taplin M-E, Bubley GJ, Shuster TD et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 1995; 332: 1393-8.
4. Klocker H, Culig Z, Hobisch A, Cato ACB, Bartsch G. Androgen receptor alterations in prostatic carcinoma. Prostate 1994; 25: 266-73.
5. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: Relation to antiandrogen withdrawal syndrome. Prostate 1996; 29: 153-8.
6. Labrie F, Dupont A, Giguere M et al. Benefits of combination therapy with flutamide in patients relapsing after castration. Br. J. Urol. 1988; 61: 341-6.
7. Yeh S, Miyamoto H, Chang C. Hydroxyflutamide may not always be a pure antiandrogen. Lancet 1997; 349: 852-3.
8. Miyamoto H, Yeh S, Wilding G, Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc. Natl Acad. Sci. USA 1998; 95: 7379-84.
9. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E. Anti-androgens and the mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 1992; 31: 2393-9.
10. Berrevoets CA, Veldscholte J, Mulder E. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors. J. Steroid Biochem. Mol. Biol. 1993; 46: 731-6.
11. Kuil CW, Mulder E. Deoxyribonucleic acid-binding ability of androgen receptors in whole cells: Implications for the action of androgens and antiandrogens. Endocrinology 1996; 137: 1870-7.
12. 5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc. Natl Acad. Sci. USA 1998; 95: 11083-8.